title: Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study.
abstract: OBJECTIVE
  To determine whether the creatinine/cystatin C (Cr/CysC) ratio, which is influenced by muscle mass, can be used as a predictive marker of the adverse effects of chemotherapy.
  
  
  METHODS
  This single-centre, retrospective, observational study assessed patients with lung cancer. Serum Cr and CysC levels were measured once within 1 month prior the commencement of chemotherapy.
  
  
  RESULTS
  A total of 25 patients with lung cancer were enrolled in the study: 22 received first-line therapy; three received second-line therapy. A significant difference was noted regarding the Cr/CysC ratios between patients with nonsmall-cell lung cancer (NSCLC) and those with small-cell lung cancer (0.78 versus 0.92, respectively). A significant difference was also noted in the Cr/CysC ratios of patients with NSCLC with toxicity grades <3 and ≥3 (0.84 versus 0.70, respectively). Similar findings were observed in patients with NSCLC who received platinum-based combination therapy (toxicity grade < 3, 0.85; toxicity grade ≥3, 0.69).
  
  
  CONCLUSIONS
  The Cr/CysC ratio could serve as a useful predictive marker for chemotherapy-related adverse effects in patients with NSCLC.
authors.affiliation: Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan khiro.tm@gmail.com.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Suzuki
authors.affiliation: Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Furuse
authors.affiliation: Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tsuda
authors.affiliation: Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Masaki
authors.affiliation: First Department of Medicine, Toyama University Hospital, Toyama, Japan.
authors.forename: Seisuke
authors.initials: S
authors.lastname: Okazawa
authors.affiliation: First Department of Medicine, Toyama University Hospital, Toyama, Japan.
authors.forename: Kenta
authors.initials: K
authors.lastname: Kambara
authors.affiliation: First Department of Medicine, Toyama University Hospital, Toyama, Japan.
authors.forename: Minehiko
authors.initials: M
authors.lastname: Inomata
authors.affiliation: First Department of Medicine, Toyama University Hospital, Toyama, Japan.
authors.forename: Toshiro
authors.initials: T
authors.lastname: Miwa
authors.affiliation: First Department of Medicine, Toyama University Hospital, Toyama, Japan.
authors.forename: Shoko
authors.initials: S
authors.lastname: Matsui
authors.affiliation: Department of Medical Oncology, Toyama University Hospital, Toyama, Japan.
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Kashii
authors.affiliation: Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Taniguchi
authors.affiliation: First Department of Medicine, Toyama University Hospital, Toyama, Japan.
authors.forename: Ryuji
authors.initials: R
authors.lastname: Hayashi
authors.affiliation: First Department of Medicine, Toyama University Hospital, Toyama, Japan.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Tobe
mesh_terms: D015415:Biomarkers / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood; D003404:Creatinine / Q000097:blood*; D055316:Cystatin C / Q000097:blood*; D003710:Demography; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D015415:Biomarkers; D055316:Cystatin C; D003404:Creatinine
keywords: Creatinine/cystatin C; adverse effect; chemotherapy; sarcopenia